Fig. 6.

Knockdown of circPHLPP2 enhances the efficacy of anti-PD-1 treatment in vivo. a-c The volume (a) and weight (b) of tumor allografts in C57 mice after subcutaneous inoculation with MC38 cells with or without circPhlpp2 knockdown. After the treatment with anti-PD-1 antibody, tumors were extracted and photographed (c) (n = 7). d-f The volume (d) and weight (e) of tumor allografts in BALB/c mice after subcutaneous inoculation with CT26 cells with or without circPhlpp2 knockdown. After the treatment with anti-PD-1 antibody, tumors were extracted and photographed (f) (n = 6). g Schematic diagram illustrating that circPHLPP2 facilitates CRC cell progression by enhancing the expression of IL36γ through its interaction with ILF3, ultimately reducing NK cell infiltration as well as granzyme B and IFN-γ expression levels of NK cells. Targeting circPHLPP2 may enhance the efficacy of anti-PD-1 therapy in CRC patients (By Figdraw). Data in a and d were calculated by two‑way ANOVA test. Data in b and e were calculated by one‑way ANOVA test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001